A regional platform, built one authorisation at a time.

Market access in pharmaceuticals is not a map exercise. Trade agreements create routes to investigate, not automatic entry — every combination of product and country carries its own registration, origin, pricing and tender requirements.

Sequencing

Three concentric horizons.

Each is entered only when the one before it is operating — not in parallel, and not on a fundraising timetable.

Operating base
A single market where the supply model is proven end to end: registration, importation, quality, pharmacovigilance, safety stock and measured service levels.
Regional markets
Neighbouring markets entered through their own national registration routes, with market-specific packaging and regional inventory established before any broad manufacturing claim is made.
Wider international
Larger markets requiring additional regulatory and commercial capability, local representation and qualified partners — developed only once regional operations are genuinely active.

What governs access

Five things that decide whether a market is real.

A trade agreement is one input among several. These are the questions we work through before a country is treated as a market rather than a hypothesis.

Registration route

Does a recognised pathway exist for this product, and what does it require in dossier, sample and timeline terms? Reliance and recognition routes can shorten this considerably — where they apply.

Origin rules

Preferential access depends on where a product is made and how much value is added there. A medicine manufactured in one country does not automatically qualify for another’s preferential tariff.

Partner quality

Storage conditions, cold chain where required, recall capability, financial standing, and a willingness to be measured on service levels rather than volume alone.

Tender timing and pricing

Public procurement cycles determine when entry is even possible. Reference pricing and tender structure determine whether it is viable at a landed cost that holds.

Payment and country risk

Foreign exchange access, payment reliability, sanctions exposure and political risk are assessed per market. Some remain strategic options requiring separate compliance diligence rather than near-term plans.

A note on sequencing

The order is the strategy.

It is tempting to open several markets at once. The addressable numbers look better and the story sounds bigger.

In practice, a programme that enters three countries before it has proven service levels in one ends up with three underperforming registrations and no evidence base. We would rather be measurably good in one market and expand from a record than be nominally present in five.

Next step

Is your market one we should be looking at?

We are interested in health systems where availability is the presenting problem — not only where the commercial opportunity is largest.